1597 related articles for article (PubMed ID: 32988401)
61. CAFs-Associated Genes (CAFGs) in Pancreatic Ductal Adenocarcinoma (PDAC) and Novel Therapeutic Strategy.
Yamashita K; Kumamoto Y
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892190
[TBL] [Abstract][Full Text] [Related]
62. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.
Askan G; Sahin IH; Chou JF; Yavas A; Capanu M; Iacobuzio-Donahue CA; Basturk O; O'Reilly EM
BMC Cancer; 2021 Apr; 21(1):385. PubMed ID: 33836674
[TBL] [Abstract][Full Text] [Related]
63. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
[TBL] [Abstract][Full Text] [Related]
64. A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma.
Yang H; Zhang W; Ding J; Hu J; Sun Y; Peng W; Chu Y; Xie L; Mei Z; Shao Z; Xiao Y
Front Immunol; 2022; 13():970588. PubMed ID: 36148233
[TBL] [Abstract][Full Text] [Related]
65. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma.
Sandhu V; Labori KJ; Borgida A; Lungu I; Bartlett J; Hafezi-Bakhtiari S; Denroche RE; Jang GH; Pasternack D; Mbaabali F; Watson M; Wilson J; Kure EH; Gallinger S; Haibe-Kains B
JCO Clin Cancer Inform; 2019 May; 3():1-16. PubMed ID: 31070984
[TBL] [Abstract][Full Text] [Related]
66. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
[TBL] [Abstract][Full Text] [Related]
67. Transcriptomic landscape of endothelial cells: Key tumor microenvironment components indicating variable clinical outcomes in pancreatic ductal adenocarcinoma.
Xie P; Tan SY; Li HF; Tang HD; Zhou JH
Environ Toxicol; 2024 Feb; 39(2):572-582. PubMed ID: 37449672
[TBL] [Abstract][Full Text] [Related]
68. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
69. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
[No Abstract] [Full Text] [Related]
70. Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas.
Gutiérrez ML; Corchete L; Teodosio C; Sarasquete ME; del Mar Abad M; Iglesias M; Esteban C; Sayagues JM; Orfao A; Muñoz-Bellvis L
Oncotarget; 2015 Aug; 6(22):19070-86. PubMed ID: 26053098
[TBL] [Abstract][Full Text] [Related]
71. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
72. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
73. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.
Hosein AN; Huang H; Wang Z; Parmar K; Du W; Huang J; Maitra A; Olson E; Verma U; Brekken RA
JCI Insight; 2019 Jul; 5(16):. PubMed ID: 31335328
[TBL] [Abstract][Full Text] [Related]
74. Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells.
Dimitrov-Markov S; Perales-Patón J; Bockorny B; Dopazo A; Muñoz M; Baños N; Bonilla V; Menendez C; Duran Y; Huang L; Perea S; Muthuswamy SK; Al-Shahrour F; Lopez-Casas PP; Hidalgo M
Mol Cancer Ther; 2020 Aug; 19(8):1751-1760. PubMed ID: 32499301
[TBL] [Abstract][Full Text] [Related]
75. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
76. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma.
Zhang J; Sun H; Liu S; Huang W; Gu J; Zhao Z; Qin H; Luo L; Yang J; Fang Y; Ge J; Ni B; Wang H
Aging (Albany NY); 2020 Nov; 12(22):23217-23232. PubMed ID: 33221741
[TBL] [Abstract][Full Text] [Related]
77. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.
Ligorio M; Sil S; Malagon-Lopez J; Nieman LT; Misale S; Di Pilato M; Ebright RY; Karabacak MN; Kulkarni AS; Liu A; Vincent Jordan N; Franses JW; Philipp J; Kreuzer J; Desai N; Arora KS; Rajurkar M; Horwitz E; Neyaz A; Tai E; Magnus NKC; Vo KD; Yashaswini CN; Marangoni F; Boukhali M; Fatherree JP; Damon LJ; Xega K; Desai R; Choz M; Bersani F; Langenbucher A; Thapar V; Morris R; Wellner UF; Schilling O; Lawrence MS; Liss AS; Rivera MN; Deshpande V; Benes CH; Maheswaran S; Haber DA; Fernandez-Del-Castillo C; Ferrone CR; Haas W; Aryee MJ; Ting DT
Cell; 2019 Jun; 178(1):160-175.e27. PubMed ID: 31155233
[TBL] [Abstract][Full Text] [Related]
78. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
79. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.
Zhou L; Zhang WG; Wang DS; Tao KS; Song WJ; Dou KF
Oncol Rep; 2014 Oct; 32(4):1734-40. PubMed ID: 25109303
[TBL] [Abstract][Full Text] [Related]
80. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
